Article

Mast cell inhibitor R112 is well tolerated and affects prostaglandin D-2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis

National Research Center (CO, USA), Boulder, Colorado, United States
Allergy and Asthma Proceedings (Impact Factor: 3.35). 05/2006; 27(3):208-13. DOI: 10.2500/aap.2006.27.2861
Source: PubMed

ABSTRACT Understanding of the role played by mast cells in allergic rhinitis (AR) has led to the development of novel therapies. The aim of this study was to determine the safety and tolerability of R112, an inhibitor of the tyrosine kinase Syk, in an allergen challenge model of AR. We also examined the effects of R112 on symptoms, mediator release, and nasal airway volumes. This double-blinded, randomized, placebo-controlled, crossover trial enrolled 20 out-of-season volunteers with AR. One intranasal dose of R112 or vehicle was administered and followed by an allergen challenge. In addition to safety monitoring, symptoms; changes in histamine, tryptase, and prostaglandin D2 (PGD2) content of nasal secretions; and acoustic rhinometry were determined over a 15-minute period. R112 was well tolerated. Adverse events were similar between treatments. Five minutes after allergen instillation, PGD2 was decreased when subjects received R112 compared with vehicle (93.4 +/- 23.0 pg/mL versus 171.6 +/- 23.0 pg/mL; p = 0.03), and this correlated with rhinorrhea (p = 0.05). However, at 10 minutes, changes in PGD2, tryptase, and histamine were not significant (46.8 +/- 9.2 pg/mL versus 68.6 +/- 9.2 pg/mL, p = 0.1; 9.5 +/- 2.7 ng/mL versus 16.6 +/- 2.9 ng/mL, p = 0.09; and 1.5 +/- 1.6 ng/mL versus 3.5 +/- 1.6 ng/mL, p = 0.4). No differences were found in symptoms or in acoustic rhinometry between treatment groups. Single-dose R112 appears safe and significantly reduces PGD2 but not histamine or tryptase release in response to allergen challenge in subjects with AR.

0 Followers
 · 
116 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Spleen tyrosine kinase (Syk), a member of Syk family of non-receptor protein tyrosine kinases plays a significant role in the immune cell signaling in B cells, mast cells, macrophages and neutrophils. Anomalous regulation of this kinase can lead to different allergic disorders and antibody-mediated autoimmune diseases such as rheumatoid arthritis, asthma, psoriasis and allergic rhinitis. Being involved in the growth and survive mechanism of B cells, its inhibition can be beneficial in B-cell lymphoma. Thus, Syk can be sited as a therapeutically relevant target for various allergic and autoimmune disorders. This review article describes the structure of Syk and its role in B-cell signaling. In addition to this, data regarding small molecule inhibitors of Syk has also been reviewed from different papers and patents published.
    European Journal of Medicinal Chemistry 07/2013; 67C:434-446. DOI:10.1016/j.ejmech.2013.04.070 · 3.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Spleen tyrosine kinase (SYK) plays a crucial role in the coordination of immune recognition receptors and orchestrates multiple downstream signaling pathways in various hematopoietic cells. In addition to its well-known function in transducing Fcγ receptor-and B cell receptor-mediated events, SYK signals downstream of a growing list of immunoreceptor pathways that modulate the innate and adaptive immune responses. SYK has been implicated in the pathogenesis of hematological malignancies including B-lineage leukemias and lymphomas. Inhibition of SYK promotes apoptosis in leukemia and lymphoma cells. Notably, SYK-dependent functions in various cell types are important in the etiology of autoimmune, allergic and neoplastic disorders. Rationally designed small molecule inhibitors targeting the ATP or the substrate binding P site of SYK have been developed with multifunctional properties. Several ATP-binding site inhibitors are under clinical trial in patients with rheumatoid arthritis, autoimmune thrombocytopenic purpura, B-cell lymphomas, allergic rhinitis and asthma. Preclinical as well as early clinical evidence shows the therapeutic potential of targeting SYK in pediatric and adult B-lineage leukemias and lymphomas. Notably, a P site SYK inhibitor C-61 was found to overcome the radiochemotherapy resistance of leukemic cells. Targeting SYK with nanotechnology-enabled delivery of C-61 to leukemia cells may overcome resistance to radiation therapy and chemotherapy as well as broaden the therapeutic window.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mast cells and basophils (MCs/Bs) play a crucial role in type I allergy, as well as in innate and adaptive immune responses. These cells mediate their actions through soluble mediators, some of which are targeted therapeutically by, for example, H1- and H2-antihistamines or cysteinyl leukotriene receptor antagonists. Recently, considerable progress has been made in developing new drugs that target additional MC/B mediators or receptors, such as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, prostaglandin D2, and proinflammatory cytokines. Mediator production can be abrogated by the use of inhibitors directed against key intracellular enzymes, some of which have been used in clinical trials (eg, inhibitors of spleen tyrosine kinase, phosphatidylinositol 3-kinase, Bruton tyrosine kinase, and the protein tyrosine kinase KIT). Reduced MC/B function can also be achieved by enhancing Src homology 2 domain-containing inositol 5' phosphatase 1 activity or by blocking sphingosine-1-phosphate. Therapeutic interventions in mast cell-associated diseases potentially include drugs that either block ion channels and adhesion molecules or antagonize antiapoptotic effects on B-cell lymphoma 2 family members. MCs/Bs express high-affinity IgE receptors, and blocking their interactions with IgE has been a prime goal in antiallergic therapy. Surface-activating receptors, such as CD48 and thymic stromal lymphopoietin receptors, as well as inhibitory receptors, such as CD300a, FcγRIIb, and endocannabinoid receptors, hold promising therapeutic possibilities based on preclinical studies. The inhibition of activating receptors might help prevent allergic reactions from developing, although most of the candidate drugs are not sufficiently cell specific. In this review recent advances in the development of novel therapeutics toward different molecules of MCs/Bs are presented.
    The Journal of allergy and clinical immunology 04/2014; 134(3). DOI:10.1016/j.jaci.2014.03.007 · 11.25 Impact Factor